Collectively, these results suggest that R428 blocks tumour perivascular cell EV‐Gas6‐mediated activation of the Axl signalling pathway in EPCs, enhances the therapeutic efficacy of regorafenib, and increases the survival time of mice with metastatic colorectal cancer. Here, AXL is linked to metastatic colorectal cancer.